will be available for inspection and copying at its principal office in accordance with Section 4.9(b)(6)(ii) of the Commission's Rules of Practice (16 CFR 4.9(b)(6)(ii)).

Analysis of Proposed Consent Order To Aid Public Comment

The Federal Trade Commission has accepted, subject to final approval, an agreement containing a consent order from Sharp Electronics Corporation (''Sharp'').

The proposed consent order has been placed on the public record for thirty (30) days for receipt of comments by interested persons. Comments received during this period will become part of the public record. After thirty (30) days, the Commission will again review the agreement and the comments received, and will decide whether it should withdraw from the agreement or make final the agreement's proposed order.

Sharp advertises and sells the ''Mobilon'' line of hand-held personal computers (''HPCs''). Sharp's Mobilon HPCs, as well as similar devices from several other manufacturers, use the Microsoft Windows CE operating system. This operating system and several applications, including a word processor, a spreadsheet, and a database, are installed on these devices' ROM board. HPCs are designed to be upgradeable to newer versions of the operating system and/or applications through the purchase and installation of a new ROM board.

This matter concerns allegedly false and deceptive advertising of Sharp's Mobilon HPCs. The Commission's proposed complaint alleges that Sharp claimed that it would offer to its Mobilon customers an upgrade to a later version of the Microsoft Windows CE operating system when such a later version became available. In fact, Sharp never offered to its Mobilon customers an upgrade to a later version of the Microsoft Windows CE operating system when such a later version became available. Further, the company continued to represent that its Mobilon HPCs were upgradeable for several months after deciding not to offer an upgrade.

The proposed consent order contains provisions designed to prevent Sharp from engaging in similar acts and practices in the future. Part I of the proposed Order prohibits the company from misrepresenting the availability of any upgrade product. Part II of the proposed order requires Sharp to offer the promised upgrade to consumers who purchased a Mobilon 4100, 4500, or 4600 handheld PC. Under this provision, Mobilon owners may obtain the upgrade for the payment of a shipping and handling charge of $10. Parts III through VI of the proposed order are reporting and compliance provisions. Part VII is a provision ''sunsetting'' the order after twenty years, with certain exceptions.

The purpose of this analysis is to facilitate public comment on the proposed order. It is not intended to constitute an official interpretation of the agreement and proposed order or to modify in any way their terms.

By the direction of the Commission.

Donald S. Clark,

Secretary.

[FR Doc. 01–3193 Filed 2–6–01; 8:45 am]

BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Notice of Interest Rate on Overdue Debts

January 31, 2001.

Section 30.13 of the Department of Health and Human Services' claims collection regulations (45 CFR part 30) provides that the Secretary shall charge an annual rate of interest as fixed by the Secretary of the Treasury after taking into consideration private consumer rates of interest prevailing on the date that HHS becomes entitled to recovery. The rate generally cannot be lower than the Department of Treasury's current value of funds rate or the applicable rate determined from the ''Schedule of Certified Interest Rates with Range of Maturities.'' This rate may be revised quarterly by the Secretary of the Treasury and shall be published quarterly by the Department of Health and Human Services in the **Federal Register**.

The Secretary of the Treasury has certified a rate of 14⅛% for the quarter ended December 31, 2000. This interest rate will remain in effect until such time as the Secretary of the Treasury notifies HHS of any change.

Dated: January 31, 2001.

George Strader,

Deputy Assistant Secretary, Finance.

[FR Doc. 01–3154 Filed 2–6–01; 8:45 am]

BILLING CODE 4150–04–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[60Day–01–19]

Proposed Data Collections Submitted for Public Comment and Recommendations

In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 for opportunity for public comment on proposed data collection projects, the Centers for Disease Control and Prevention (CDC) will publish periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the data collection plans and instruments, call the CDC Reports Clearance Officer on (404) 639–7090.

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques for other forms of information technology. Send comments to Anne O'Connor, CDC Assistant Reports Clearance Officer, 1600 Clifton Road, MS–D24, Atlanta, GA 30333. Written comments should be received within 60 days of this notice.

Proposed Project

Evaluating HIV Prevention Programs in Community-Based Organizations (CBOs)—New—The Centers for Disease Control and Prevention (CDC), National Center for HIV, STD, and TB Prevention (NCHSTP) proposes to develop and test a model of HIV prevention community-based organization (CBO) functioning using a one time data collection questionnaire. Each CBO will be asked to answer questions related to the existence and importance of factors affecting their HIV prevention interventions. This data collection is necessary for CDC to better (a) assess CBO applications systematically for funding, (b) develop materials CBOs can use to assess their own programmatic needs and create a social map of their target populations, including a CBO profile of organizational, environmental, target population, intervention program

and accomplishments characteristics, (c) better develop CBO technical assistance (TA) materials, and (d) provide TA to CBOs that have already been selected by CDC for funding. This study will also yield more hypotheses for statistical testing, instruments with reliability and validity data for use in other studies, and a model that can be used and revised to meet the context of a particular CBO. The questionnaire will be administered to 766 CBOs that have applied for CDC funding under program announcements 00023, 00100, 99047, 99091, 99092, 99096. The total annual cost to respondents is estimated at $26,044 based on an average salary of $35,000 ($17.00 per hour) for program managers.

Respondents	No. of respondents	No. of responses per respondent	Average burden per response (in hrs.)	Total burden (in hrs.)
Model Survey	766	1	2	1532
Total	.....	.....	.....	1532

Dated: February 1, 2001.

Nancy Cheal,

Acting Associate Director for Policy, Planning, and Evaluation, Centers for Disease Control and Prevention (CDC).

[FR Doc. 01–3178 Filed 2–6–01; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Delegations of Authority

Notice is hereby given that on January 19, 2001 the Director of Child Support Enforcement redelegated to the Deputy Commissioner of Child Support Enforcement, all the authorities delegated to the Deputy Director/Commissioner of Child Support Enforcement by the Director of Child Support Enforcement. This delegation is subject to any limitations or conditions contained in the delegations to the Deputy Director/Commissioner.

Dated: January 19, 2001.

Olivia A. Golden,

Director, Child Support Enforcement.

[FR Doc. 01–3114 Filed 2–6–01; 8:45 am]

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 00D–1651]

Devices—Inspections of Medical Device Manufacturers Compliance Program Guidance Manual, CP 7382.845; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a compliance program (CP) entitled ''Inspection of Medical Device Manufacturers.'' This CP is intended to help FDA components and industry comply with FDA's internal inspection and compliance processes concerning quality system/good manufacturing practice (QS/GMP) inspections of manufacturers of medical devices.

DATES: Submit written comments on this CP at any time.

ADDRESSES: Submit written requests for single copies of CP 7382.845 ''Inspections of Medical Device Manufacturers'' to the Freedom of Information Office (HFI–35), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857. Copies of the CP may also be downloaded to a personal computer with access to the Internet. The Office of Regulatory Affairs (ORA) home page includes the CP and may be accessed at http://www.fda.gov/ora. The CP will be available on the compliance references page for ORA. Submit written comments on the CP to the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: *Technical questions concerning inspections of medical device manufacturers:* Denise D. Dion, Division of Emergency and Investigational Operations (HFC–130), Office of Regional Operations, Office of Regulatory Affairs, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–5645, FAX 301–443–6919.

Questions concerning regulatory actions and all comments: Wes W. Morgenstern, Division of Program Operations (HFZ–305), Office of Compliance, Center for Devices and Radiological Health, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–594–4699, FAX 301–594–4715.

SUPPLEMENTARY INFORMATION: FDA has renumbered CP 7382.830 as CP 7382.845 and revised it to reflect a change in the guidance on how a QS/GMP inspection of a medical device manufacturer should be conducted. The new inspectional method is known as the quality systems inspection technique. The revision to the CP also reflects changes in when FDA may consider a firm out of compliance with the medical device quality system regulation (21 CFR part 820).

The CP is intended to provide policy and regulatory guidance to FDA's field and headquarters staff with regard to medical device manufacturer inspections. It also contains information that may be useful to the regulated industry and to the public.

The CP is being issued as a guidance document and represents the agency's current thinking on the subject. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. FDA published a notice making a draft of the CP available for public comment in the **Federal Register** (64 FR 44024, August 12, 1999).

The agency has adopted good guidance practice (GGP) regulations (65 FR 56468, September 19, 2000) that set forth the agency's policies and procedures for the development, issuance, and use of guidance documents. This CP is issued as a level 1 guidance consistent with GGP's.

Interested persons may submit to the Dockets Management Branch (address above) written comments regarding the CP entitled ''Inspections of Medical Device Manufacturers'' at any time. Two copies of any comments are to be submitted, except individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. A copy of the CP and